Business Wire

CorFlow Announces Positive Data from the MOCA I First in Human Study Presented at EuroPCR 2023


CorFlow Therapeutics AG, a clinical-stage company that has developed the world’s first combined system for diagnostic assessment and therapy delivery to address coronary microvascular obstruction (MVO), has announced the interim positive results of its MOCA I (Microvascular Obstruction with CoFI System Assessment) study at EuroPCR in Paris, France. The first-in-human study aims to evaluate the safety and feasibility of a novel real-time catheter-based system to detect MVO immediately after primary percutaneous coronary intervention (PPCI) and deliver timely therapeutic intracoronary agents. The data set presented in a EuroPCR Late Breaking Trial session included 30 patients with an ST elevation myocardial infarction (STEMI), the most severe type of heart attack.

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

CorFlow has developed a next-generation fully-integrated CoFI system, which will be utilized in the upcoming pivotal trial prior to be commercially available. It is an investigational device limited by federal law to investigational use and is not available for commercial distribution yet. (Photo: Business Wire)

The system outputs a novel pressure parameter (PCoFI) for detection of MVO, which was evaluated for correlation with cardiac MRI measured MVO, considered the reference standard. For the patients who had the CoFI diagnostic sequence, the essential results of the study showed that the system provided a sensitivity of 95%, specificity of 91%, and AUC of 0.94 for the ability to detect MVO measured by cardiac MRI. The CoFI device and procedure were deemed safe with no device-related deaths, flow-limiting dissections, or thrombotic events at 30 days, as adjudicated by an independent Clinical Events Committee.

The MOCA I study, presented by Professor Dr. Marco Valgimigli, Deputy Chief of Cardiology at the Cardiocentro Ticino Institute in Lugano, Switzerland, suggests that it may now be possible to have accurate, early detection which can lead to targeted treatment for these high-risk patients. Finally, we may be able to detect MVO with confidence, directly at the end of a primary PCI. This is significant. These are important findings that call for further research with this technology.”

Current interventional cardiology technologies, addressing the larger coronary arteries, have been instrumental in saving patients from death and complications after a heart attack, reducing short term mortality over the last several decades. Yet for many patients, longer term outcomes are still poor despite current standard of care treatment. MVO, which is found to be in more than 50% of heart attack patients, has been shown to be the single most powerful prognostic indicator for negative outcomes for these patients, including heart failure and death. Heart disease remains the leading cause of death worldwide, with more than 85% of these due to heart attacks and strokes. Multiple peer-reviewed studies suggest that addressing these blockages in the coronary microcirculation could reduce this global burden.

“The data presented from the MOCA I study with the CorFlow system is very encouraging for our community of cardiologists, who are increasingly recognizing MVO and microvascular disease as a next frontier to improve outcomes in our field,” stated Dr. Azeem Latib of Montefiore Medical Center, New York City, USA. “This emerging area is in its early days, but we can agree that a significant step forward is made by being able to diagnose these patients in the cath lab. With such a technology, we can imagine that many concomitant therapy options can soon be evaluated, since it is now clear that treating only the larger vessels is not enough.”

“Real-time catheter-based MVO detection can provide healthcare professionals with valuable information about the extent and severity of the heart attack, which can inform immediate treatment decisions to impact patient outcomes," stated Paul Mead, CEO of CorFlow. “The CoFI System can be a game-changer as it is the first of its kind and can potentially revolutionize the field, which is ripe for innovation that makes a difference. The ‘next big thing’ in interventional cardiology should be driven by where the largest positive impact in outcomes can be made, and it is hard to imagine a clearer target in this regard than STEMI patients with MVO, the first indication we pursued. MOCA I shows that we can, and will, do better for these patients.”

About the CorFlow CoFI System

The Controlled Flow Infusion (CoFI) System is designed for diagnostic assessment of the coronary microcirculation in the cath lab, and to be a platform for controlled infusion of physician-specified diagnostic and therapeutic agents into the microcirculation. The CoFI System uses proprietary software algorithms to detect microvascular obstruction (MVO) and potentially other conditions related to microvascular function. The system the company plans to bring to the market is comprised of a next generation console, an advanced proprietary catheter with a pressure sensor wire, and single use infusion cassette. In addition to the primary clinical target addressing heart attack patients, the company intends to pursue other indications in both coronary and broader vascular use cases with the technology which are covered by broad patent families.

About CorFlow

CorFlow Therapeutics AG, a venture-backed company headquartered in Switzerland, is advancing medical technology and cardiology in an area many are calling "the next frontier" to improve clinical outcomes for people with heart attacks and coronary artery disease. Two of the founders of the company are renowned interventional cardiologists, Dr. Rob Schwartz and Dr. Martin Rothman, who discovered acute unmet needs over decades of clinical practive. The company is currently raising its Series B round of funding to pursue its mission to save lives and achieve future milestones. The company is continuing to enroll patients in the ongoing European "MOCA I" clinical trial of the CoFI System and is working toward US study submissions for clinical trials and commercialization of its technology.

The CoFI-System is not approved in the United States of America. It is an investigational device limited by federal law to investigational use and is not available for commercial distribution.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Judy Gonzalez, +1.919.345.2212,

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Demand Increases for Project Professionals with AI Skills, Yet PMI Research Finds Only 18% Have Practical Experience26.9.2023 17:00:00 CEST | Press release

Project Management Institute (PMI), the world's leading organization for the project management profession, is empowering millions of global project professionals worldwide to adopt, embrace, and leverage artificial intelligence (AI), machine learning (ML), and generative AI (GenAI). PMI is developing the tools, resources, and learning opportunities – including a free, introductory online course entitled “Generative AI Overview for Project Managers” – project professionals need to leverage AI powered technology while preserving the human touch in project management. According to McKinsey, GenAI and other technologies have the potential to automate work activities that absorb 60 to 70 percent of employees’ time today. But tools cannot automate interpersonal skills, the invaluable and very necessary skills project managers bring to projects. Communication, problem-solving, collaborative leadership, and strategic thinking – skills PMI calls “power skills” – will continue to be crucial to

Aktana Announces New Strategy Suite to Give Biopharma Leaders Unprecedented Visibility and Control Over Omnichannel Campaign Effectiveness26.9.2023 17:00:00 CEST | Press release

Today, at the inaugural Aktana Innovation Exchange (AIx) event, Aktana, Inc., the leader in intelligent customer engagement for the global life sciences industry, announced three new products that transform customer engagement programs by dynamically tightening the connection between strategy, tactical execution and time to impact. AIx is a collaborative event hosting executives from more than 35 life sciences and technology companies with the sole mission of improving the rate of innovation in applying AI and machine learning to commercial and medical programs. In recent research conducted by Aktana with 20 biopharma companies, more than 75% of respondents cited a severe challenge in achieving direct line of sight of how strategies are being executed in the field and knowing when tactics should be modified. The gap between strategy and delivering precision execution of pharmaceutical commercial campaigns is a constant hurdle across the industry, with new drug launches failing to meet

Improbable ventures into new worlds, unveils robust financial performance, underpinned by exciting innovation developments and standout progress made through recent sports events26.9.2023 16:30:00 CEST | Press release

This press release features multimedia. View the full release here: (Graphic: Business Wire) Highlights With a combination of gaming technology, new AI capabilities and metaverse infrastructure, the metaverse is delivering more interesting, exciting and useful experiences, boosted by the creator economy.For instance, sports has taken the lead in investments and ambitious projects, driven by the appetite of current and new fans for exclusive, fun content that enables them to consume their sport in a unique fashion with their community, and allowing rights owners new and innovative ways to monetize their content. Having completed its transformation, Improbable is now clarifying its brand mission as a venture builder, creating new ventures based upon its own backbone technology. The company has reorganized and now has three primary areas of activities: Metaverse technology development Metaverse and metaversal experiences developmen

ClickHouse Announces ClickPipes: A Continuous Data Ingestion Service for ClickHouse Cloud26.9.2023 16:16:00 CEST | Press release

ClickHouse Inc., creator of the popular open-source columnar database designed for real-time analytics, today announces the general availability of ClickPipes, which connects external data sources directly into ClickHouse Cloud. ClickPipes allows users to set up continuous data pipelines in just a few clicks and launches with integrations for Confluent Cloud, Amazon MSK and Apache Kafka, with plans to add more. This press release features multimedia. View the full release here: ClickPipes powers seamless data ingestion for real-time analytics (Graphic: Business Wire) “Setting up reliable data pipelines can be a tedious task. By providing a user-friendly continuous ingestion experience for ClickHouse Cloud, users can now focus on what really matters: extracting insights from their data,” says Aaron Katz, Co-founder and CEO of ClickHouse, Inc. “Besides its existing connectors, ClickPipes also represents the foundation of a serverl

Quectel showcases EG916Q-GL Cat 1 bis module at MWC Las Vegas 202326.9.2023 16:00:00 CEST | Press release

Quectel Wireless Solutions, a global IoT solutions provider, is delighted to announce the EG916Q-GL, a globally cost-optimized Cat 1 bis module based on the Qualcomm® QCX216 LTE IoT modem from Qualcomm Technologies, Inc. and ideally suited for a wide spectrum of applications globally. These include but are not limited to asset management, telematics, payment solutions, remote monitoring and control, security and automation, and smart metering, among others. This press release features multimedia. View the full release here: Quectel showcases EG916Q-GL Cat 1 bis module at MWC Las Vegas 2023 (Photo: Business Wire) The Quectel EG916Q-GL stands as an LTE Cat 1 bis module optimized for M2M and IoT applications. Leveraging the advanced 3GPP Rel-14 LTE technology, it boasts impressive data rates of up to 10 Mbps on the downlink and 5 Mbps on the uplink. This module is designed in a compact and unified form factor, ensuring compatibilit